The London-listed group has asked its advisers to renew its bid effort almost four months after Baxalta rejected an unsolicited USD 30 billion offer that it said significantly undervalued the company.

1. Shire's bid preparations come three weeks after it announced its USD 5.9 billion purchase of US rare disease specialist Dyax Corp.

2. Shire is working with Morgan Stanley, Evercore  and Deutsche Bank on the offer which could be structured in cash and shares.

4. Baxalta, which has a market capitalization of USD 22.7 billion would help complement Shire's growing portfolio of high-priced treatments for rare or 'orphan' diseases.

5. Baxalta's shares rose to an intra-day high of USD 37.50, up more than 10 percent before trimming gains to USD 35.67 at 2105 GMT.

Latest News  from Business News Desk